Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients.

ABSTRACT:

Context

Vitamin D3 might benefit prostate cancer (PCa) patients because prostate cells can locally synthesize the active hormone calcitriol.

Objective

Our objective was to determine the effects of oral vitamin D3 on vitamin D metabolites and PCa proliferative activity in prostate tissue.

Design and setting

We conducted a double-blind randomized clinical trial at surgical oncology clinics in Toronto, Canada.

Patients

PCa patients (Gleason 6 or 7) participated in the study. Of 66 subjects who were enrolled, 63 completed the dosing protocol.

Intervention

Vitamin D3 (400, 10 000, or 40 000 IU/d) was orally administered before radical prostatectomy.

Main outcome measures

We evaluated vitamin D metabolite levels and Ki67 labeling in surgical prostate ti

SUBMITTER: Wagner D 

PROVIDER: S-EPMC11651370 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature